(Q24247134)

English

Platinum containing regimens for metastatic breast cancer

scientific article

In more languages

edit

Statements

0 references

0 references

1 reference

Europe PubMed Central

title

Platinum containing regimens for metastatic breast cancer (English)

0 references

1 reference

metastatic breast cancer

1 reference

3

0 references

Davina Ghersi

series ordinal

2

0 references

author name string

Sue Carrick

series ordinal

1

0 references

John Simes

series ordinal

4

0 references

publication date

19 April 2004

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

21 January 2018

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

21 January 2018

Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

21 January 2018

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

21 January 2018

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

21 January 2018

The platinum agents: a role in breast cancer treatment?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

21 January 2018

Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

21 January 2018

Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of serum tetranectin in patients with metastatic breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD003374.PUB3

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD003374.PUB3

0 references

PubMed publication ID

15266482

0 references

(Q24247134)

Platinum containing regimens for metastatic breast cancer

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)